Display options
Cite
Borden ES, Adams AC, Buetow KH, et al. Shared Gene Expression and Immune Pathway Changes Associated with Progression from Nevi to Melanoma. Cancers (Basel). 2021;14(1)doi: 10.3390/cancers14010003.
Borden, E. S., Adams, A. C., Buetow, K. H., Wilson, M. A., Bauman, J. E., Curiel-Lewandrowski, C., Chow, H. S., LaFleur, B. J., & Hastings, K. T. (2021). Shared Gene Expression and Immune Pathway Changes Associated with Progression from Nevi to Melanoma. Cancers, 14(1), . https://doi.org/10.3390/cancers14010003
Borden, Elizabeth S, et al. "Shared Gene Expression and Immune Pathway Changes Associated with Progression from Nevi to Melanoma." Cancers vol. 14,1 (2021). doi: https://doi.org/10.3390/cancers14010003
Borden ES, Adams AC, Buetow KH, Wilson MA, Bauman JE, Curiel-Lewandrowski C, Chow HS, LaFleur BJ, Hastings KT. Shared Gene Expression and Immune Pathway Changes Associated with Progression from Nevi to Melanoma. Cancers (Basel). 2021 Dec 21;14(1). doi: 10.3390/cancers14010003. PMID: 35008167; PMCID: PMC8749980.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 Dec 21;14(1). doi: 10.3390/cancers14010003.

Shared Gene Expression and Immune Pathway Changes Associated with Progression from Nevi to Melanoma.

Cancers

Elizabeth S Borden, Anngela C Adams, Kenneth H Buetow, Melissa A Wilson, Julie E Bauman, Clara Curiel-Lewandrowski, H-H Sherry Chow, Bonnie J LaFleur, Karen Taraszka Hastings

Affiliations

  1. Department of Basic Medical Sciences, University of Arizona College of Medicine Phoenix, Phoenix, AZ 85004, USA.
  2. Phoenix Veterans Affairs Health Care System, Phoenix, AZ 85012, USA.
  3. School of Life Sciences, Arizona State University, Tempe, AZ 85281, USA.
  4. Center for Evolution and Medicine, Arizona State University, Tempe, AZ 85281, USA.
  5. Department of Medicine, University of Arizona College of Medicine Tucson, Tucson, AZ 85724, USA.
  6. University of Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA.
  7. BIO5 Institute, University of Arizona, Tucson, AZ 85724, USA.

PMID: 35008167 PMCID: PMC8749980 DOI: 10.3390/cancers14010003

Abstract

There is a need to identify molecular biomarkers of melanoma progression to assist the development of chemoprevention strategies to lower melanoma incidence. Using datasets containing gene expression for dysplastic nevi and melanoma or melanoma arising in a nevus, we performed differential gene expression analysis and regularized regression models to identify genes and pathways that were associated with progression from nevi to melanoma. A small number of genes distinguished nevi from melanoma. Differential expression of seven genes was identified between nevi and melanoma in three independent datasets. C1QB, CXCL9, CXCL10, DFNA5 (GSDME), FCGR1B, and PRAME were increased in melanoma, and SCGB1D2 was decreased in melanoma, compared to dysplastic nevi or nevi that progressed to melanoma. Further supporting an association with melanomagenesis, these genes demonstrated a linear change in expression from benign nevi to dysplastic nevi to radial growth phase melanoma to vertical growth phase melanoma. The genes associated with melanoma progression showed significant enrichment of multiple pathways related to the immune system. This study demonstrates (1) a novel application of bioinformatic approaches to aid clinical trials of melanoma chemoprevention and (2) the feasibility of determining a gene signature biomarker of melanomagenesis.

Keywords: dysplastic nevi; melanoma; molecular biomarkers

References

  1. Cancer. 2012 Dec 1;118(23):5848-56 - PubMed
  2. Am J Surg Pathol. 2018 Nov;42(11):1456-1465 - PubMed
  3. Nat Commun. 2019 Apr 11;10(1):1689 - PubMed
  4. Exp Dermatol. 1998 Dec;7(6):335-41 - PubMed
  5. Cancer Prev Res (Phila). 2010 Feb;3(2):233-45 - PubMed
  6. Cancer. 2019 Jan 1;125(1):18-44 - PubMed
  7. Virchows Arch. 1999 Dec;435(6):574-9 - PubMed
  8. Genes Chromosomes Cancer. 2007 Nov;46(11):1019-27 - PubMed
  9. J Immunol. 2016 Jun 1;196(11):4783-92 - PubMed
  10. J Cutan Pathol. 2015 Apr;42(4):244-52 - PubMed
  11. Nat Rev Cancer. 2015 Feb;15(2):96-109 - PubMed
  12. Gigascience. 2019 Jul 1;8(7): - PubMed
  13. J Stat Softw. 2010;33(1):1-22 - PubMed
  14. Science. 1981 Jun 5;212(4499):1151-3 - PubMed
  15. Int J Cancer. 1999 Oct 8;83(2):255-62 - PubMed
  16. Cell Metab. 2012 Dec 5;16(6):751-64 - PubMed
  17. Biol Sex Differ. 2020 Jul 21;11(1):42 - PubMed
  18. J Immunol. 1993 Sep 1;151(5):2667-75 - PubMed
  19. J Invest Dermatol. 2000 May;114(5):941-7 - PubMed
  20. Cancer Biol Ther. 2005 Sep;4(9):1018-29 - PubMed
  21. Nat Protoc. 2009;4(1):44-57 - PubMed
  22. J Invest Dermatol. 1993 Mar;100(3):322S-325S - PubMed
  23. J Immunol. 2012 Sep 1;189(5):2635-44 - PubMed
  24. Arch Dermatol. 2003 Mar;139(3):282-8 - PubMed
  25. Int J Oncol. 2007 Nov;31(5):1039-50 - PubMed
  26. Cancer Res. 2016 Jun 1;76(11):3145-55 - PubMed
  27. J Clin Invest. 1992 Nov;90(5):2102-9 - PubMed
  28. Orphanet J Rare Dis. 2017 Sep 6;12(1):150 - PubMed
  29. Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6268-72 - PubMed
  30. Front Oncol. 2021 Jul 13;11:709077 - PubMed
  31. Clin Cancer Res. 2005 Oct 15;11(20):7234-42 - PubMed
  32. Cancer Prev Res (Phila). 2014 May;7(5):496-504 - PubMed
  33. Bioinformatics. 2014 Aug 1;30(15):2114-20 - PubMed
  34. Dev Comp Immunol. 2020 Jul;108:103666 - PubMed
  35. Nat Genet. 2001 Oct;29(2):117-29 - PubMed
  36. PLoS One. 2014 Feb 18;9(2):e89491 - PubMed
  37. J Am Acad Dermatol. 1989 Feb;20(2 Pt 1):257-60 - PubMed
  38. Proteomics Clin Appl. 2014 Jun;8(5-6):427-37 - PubMed
  39. Nucleic Acids Res. 2015 Apr 20;43(7):e47 - PubMed
  40. Eur J Cancer. 2018 Mar;92:108-118 - PubMed
  41. Nat Commun. 2016 Feb 01;7:10346 - PubMed
  42. FEBS Lett. 2019 Nov;593(22):3210-3219 - PubMed
  43. Cancer Cell. 2018 Jul 9;34(1):45-55.e4 - PubMed
  44. Cancer Epidemiol Biomarkers Prev. 1993 Mar-Apr;2(2):99-101 - PubMed
  45. Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6092-7 - PubMed
  46. Arterioscler Thromb Vasc Biol. 1997 May;17(5):932-9 - PubMed
  47. Per Med. 2020 Sep;17(5):361-371 - PubMed
  48. J Am Acad Dermatol. 2017 Jan;76(1):114-120.e2 - PubMed
  49. J Natl Cancer Inst. 2009 Nov 4;101(21):1446-52 - PubMed
  50. Front Immunol. 2013 Mar 27;4:76 - PubMed
  51. Cancer Res. 1994 Jun 15;54(12):3242-7 - PubMed
  52. J Transl Med. 2008 Nov 24;6:70 - PubMed
  53. Acta Derm Venereol. 2017 Jun 9;97(6):692-697 - PubMed
  54. Clin Epigenetics. 2019 Aug 23;11(1):123 - PubMed
  55. Cancer. 1988 Jul 1;62(1):163-73 - PubMed
  56. Int J Cancer. 1999 Apr 20;84(2):160-8 - PubMed
  57. Pharmacol Res. 2019 Apr;142:50-57 - PubMed
  58. Mol Immunol. 1998 Oct;35(14-15):943-54 - PubMed
  59. Cancer Gene Ther. 2006 Apr;13(4):393-405 - PubMed
  60. CA Cancer J Clin. 2021 Jan;71(1):7-33 - PubMed
  61. J Invest Dermatol. 2005 May;124(5):1044-52 - PubMed
  62. Future Oncol. 2010 Jan;6(1):111-6 - PubMed
  63. J Exp Med. 2021 Sep 6;218(9): - PubMed
  64. Oncogene. 2014 Sep 4;33(36):4474-84 - PubMed
  65. JAMA Dermatol. 2013 Aug;149(8):928-34 - PubMed
  66. Exp Dermatol. 2019 Jan;28(1):35-44 - PubMed
  67. Proc Natl Acad Sci U S A. 2021 Mar 9;118(10): - PubMed
  68. N Engl J Med. 2015 Nov 12;373(20):1926-36 - PubMed
  69. Oncotarget. 2015 Aug 21;6(24):20636-49 - PubMed
  70. Cancer. 2017 Feb 15;123(4):617-628 - PubMed
  71. J Invest Dermatol. 2016 Oct;136(10):2030-2040 - PubMed
  72. JAMA Dermatol. 2017 Jul 1;153(7):675-680 - PubMed
  73. Genome Biol. 2014 Feb 03;15(2):R29 - PubMed
  74. J Cutan Pathol. 1983 Jun;10(3):188-92 - PubMed
  75. Cell. 2020 Aug 20;182(4):872-885.e19 - PubMed
  76. Int J Biol Markers. 2005 Oct-Dec;20(4):242-8 - PubMed
  77. Oncogene. 2018 Nov;37(47):6136-6151 - PubMed
  78. J Natl Cancer Inst. 2008 Oct 15;100(20):1432-8 - PubMed
  79. Nucleic Acids Res. 2006 Jan 23;34(2):e8 - PubMed
  80. Cancer Res. 2013 Jan 1;73(1):172-83 - PubMed
  81. Science. 2012 Apr 27;336(6080):481-5 - PubMed
  82. Br J Cancer. 2015 Jul 14;113(2):327-35 - PubMed
  83. Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1107-1113 - PubMed
  84. J Invest Dermatol. 2019 Jan;139(1):202-212 - PubMed
  85. Nat Commun. 2020 Apr 14;11(1):1769 - PubMed
  86. Oncogene. 2017 Jul 27;36(30):4243-4252 - PubMed
  87. J Cell Biol. 2019 Sep 2;218(9):3002-3018 - PubMed
  88. Life Sci. 2020 Jan 15;241:117140 - PubMed
  89. Nat Methods. 2015 Feb;12(2):115-21 - PubMed
  90. Nat Rev Immunol. 2017 Sep;17(9):559-572 - PubMed
  91. Cancers (Basel). 2021 Jul 31;13(15): - PubMed
  92. J Biol Chem. 2001 Nov 30;276(48):44926-35 - PubMed
  93. Cell. 2020 Aug 20;182(4):886-900.e17 - PubMed
  94. PLoS Med. 2012;9(5):e1001216 - PubMed
  95. Nat Methods. 2017 Apr;14(4):417-419 - PubMed
  96. Int J Cancer. 2010 Apr 15;126(8):1869-1881 - PubMed
  97. Cancer Res. 1982 Mar;42(3):980-6 - PubMed
  98. J Clin Oncol. 2015 Aug 10;33(23):2509-15 - PubMed
  99. Life Sci. 2020 Jul 1;252:117611 - PubMed
  100. Theranostics. 2020 Sep 15;10(25):11428-11443 - PubMed
  101. PLoS One. 2012;7(1):e30397 - PubMed

Publication Types

Grant support